Compare
Cogent Biosciences, Inc. vs BridgeBio Pharma, Inc. vs uniQure N.V. vs Disc Medicine, Inc.
| Latest fiscal year | Cogent Biosciences, Inc. COGT | BridgeBio Pharma, Inc. BBIO | uniQure N.V. QURE | Disc Medicine, Inc. IRON |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $502.08M | $16.10M | n/a |
| Revenue growth (YoY) | n/a | +126.3% | -40.6% | n/a |
| Gross margin | n/a | n/a | 89.5% (computed) | n/a |
| Operating margin | n/a | -104.2% | n/m | n/a |
| Net margin | n/a | -146.0% | n/m | n/a |
| Net income | -$328.94M | -$732.94M | -$198.97M | -$212.18M |
| EPS (Diluted) | -$2.16 | -$3.78 | -$3.46 | -$6.01 |
| Operating cash flow | -$264.44M | -$445.91M | -$177.96M | -$180.39M |
| Free cash flow | -$266.00M | -$447.01M | -$178.40M | -$181.33M |
| Cash & equivalents | $312.01M | $570.12M | $80.24M | $91.14M |
| Total assets | $937.61M | $936.02M | $824.91M | $806.88M |
| Total liabilities | $301.24M | $3.01B | $626.01M | $67.05M |
| Shareholders' equity | $636.37M | -$2.09B | $198.90M | $739.83M |
| Return on year-end equity | -51.7% | n/a | -100.0% | -28.7% |
| Shares outstanding | 160.98M | 194.77M | 62.34M | 37.89M |
Revenue, most recent five fiscal years
| Fiscal year | Cogent Biosciences, Inc. | BridgeBio Pharma, Inc. | uniQure N.V. | Disc Medicine, Inc. |
|---|---|---|---|---|
| Latest | $7.87M Ended 2020-12-31 | $502.08M Ended 2025-12-31 | $16.10M Ended 2025-12-31 | n/a |
| 1 year earlier | $22.50M Ended 2019-12-31 | $221.90M Ended 2024-12-31 | $27.12M Ended 2024-12-31 | n/a |
| 2 years earlier | $9.73M Ended 2018-12-31 | $9.30M Ended 2023-12-31 | $15.84M Ended 2023-12-31 | n/a |
| 3 years earlier | $8.36M Ended 2017-12-31 | $77.65M Ended 2022-12-31 | $106.48M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $69.72M Ended 2021-12-31 | $524.00M Ended 2021-12-31 | n/a |